The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Stadler, Walter M.
One or more keywords matched the following items that are connected to Stadler, Walter M.
Item TypeName
Concept Prostate-Specific Antigen
Academic Article Docetaxel and exisulind in hormone-refractory prostate cancer.
Academic Article Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Academic Article A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Academic Article A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Academic Article Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
Academic Article A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Academic Article A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.
Academic Article A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Academic Article Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Academic Article Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
Academic Article MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
Academic Article Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
Academic Article Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
Academic Article A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer.
Academic Article Nilutamide: possible utility as a second-line hormonal agent.
Academic Article Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
Academic Article Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy.
Academic Article Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.
Academic Article Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Academic Article Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Academic Article Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
Academic Article Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Academic Article Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Academic Article A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
Search Criteria
  • Prostate Specific Antigen